- Home
- SLS vs XNCR Comparison
SLS vs XNCR Comparison
Compare SLS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | XNCR |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 881.9M |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLS | XNCR |
|---|---|---|
| Price | $8.12 | $12.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 9.0M | 610.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $110.98 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $1.39 | $6.92 |
| 52 Week High | $9.51 | $18.69 |
Technical Indicators
Market Signals| Indicator | SLS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 60.65 |
| Support Level | $7.07 | $12.19 |
| Resistance Level | $9.51 | $13.69 |
| Average True Range (ATR) | 0.66 | 0.60 |
| MACD | -0.16 | 0.15 |
| Stochastic Oscillator | 44.27 | 79.06 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.